Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India
Introduction: Urinary tract infections are mostly treated empirically with broad-spectrum antibiotics which have resulted in development of multi-drug resistant strains. Limited options of newer antibiotics have necessitated the reintroduction of some old antimicrobial agents such as fosfomycin. Aim...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | CHRISMED Journal of Health and Research |
| Subjects: | |
| Online Access: | http://www.cjhr.org/article.asp?issn=2348-3334;year=2022;volume=9;issue=2;spage=125;epage=129;aulast=Jain |
| _version_ | 1828066253337526272 |
|---|---|
| author | Ruchi Jain Nita Pal Saroj Hooja |
| author_facet | Ruchi Jain Nita Pal Saroj Hooja |
| author_sort | Ruchi Jain |
| collection | DOAJ |
| description | Introduction: Urinary tract infections are mostly treated empirically with broad-spectrum antibiotics which have resulted in development of multi-drug resistant strains. Limited options of newer antibiotics have necessitated the reintroduction of some old antimicrobial agents such as fosfomycin. Aim: To evaluate the in-vitro activity of fosfomycin against uropathogenic E.coli. Method: A total of 145 E.coli isolates were identified by conventional microbiological procedures and antimicrobial susceptibility performed by Kirby-Bauer disk diffusion method. They were screened for extended spectrum β-lactamase (ESBL) production and screen positives were confirmed by phenotypic confirmatory test (CLSI). Results: Out of 145 isolates, 91 (62.76 %) were found in males and 54 (37.24%) from females. Majority of the isolates were detected in the age group of 21-30 years 48.96%. A very high susceptibility of 94.48% was observed with fosfomycin. Suceptibility to tigecycline and nitrofurantoin was 87.58 % and 77.24 % respectively. Multi-drug resistance was observed in 85.51% isolates and 45.51% were ESBL producers. Conclusion: Fosfomycin showed an excellent in vitro activity against MDR and ESBL producing E.coli, therefore it should be considered as a potential therapeutic alternative in the treatment of UTI. |
| first_indexed | 2024-04-10T23:28:06Z |
| format | Article |
| id | doaj.art-0af7455060db40a8bb959efea05077b8 |
| institution | Directory Open Access Journal |
| issn | 2348-3334 2348-506X |
| language | English |
| last_indexed | 2024-04-10T23:28:06Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | CHRISMED Journal of Health and Research |
| spelling | doaj.art-0af7455060db40a8bb959efea05077b82023-01-12T11:16:50ZengWolters Kluwer Medknow PublicationsCHRISMED Journal of Health and Research2348-33342348-506X2022-01-019212512910.4103/cjhr.cjhr_21_21Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western IndiaRuchi JainNita PalSaroj HoojaIntroduction: Urinary tract infections are mostly treated empirically with broad-spectrum antibiotics which have resulted in development of multi-drug resistant strains. Limited options of newer antibiotics have necessitated the reintroduction of some old antimicrobial agents such as fosfomycin. Aim: To evaluate the in-vitro activity of fosfomycin against uropathogenic E.coli. Method: A total of 145 E.coli isolates were identified by conventional microbiological procedures and antimicrobial susceptibility performed by Kirby-Bauer disk diffusion method. They were screened for extended spectrum β-lactamase (ESBL) production and screen positives were confirmed by phenotypic confirmatory test (CLSI). Results: Out of 145 isolates, 91 (62.76 %) were found in males and 54 (37.24%) from females. Majority of the isolates were detected in the age group of 21-30 years 48.96%. A very high susceptibility of 94.48% was observed with fosfomycin. Suceptibility to tigecycline and nitrofurantoin was 87.58 % and 77.24 % respectively. Multi-drug resistance was observed in 85.51% isolates and 45.51% were ESBL producers. Conclusion: Fosfomycin showed an excellent in vitro activity against MDR and ESBL producing E.coli, therefore it should be considered as a potential therapeutic alternative in the treatment of UTI.http://www.cjhr.org/article.asp?issn=2348-3334;year=2022;volume=9;issue=2;spage=125;epage=129;aulast=Jainescherichia colifosfomycinmulti-drug resistanceurinary tract infection |
| spellingShingle | Ruchi Jain Nita Pal Saroj Hooja Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India CHRISMED Journal of Health and Research escherichia coli fosfomycin multi-drug resistance urinary tract infection |
| title | Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India |
| title_full | Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India |
| title_fullStr | Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India |
| title_full_unstemmed | Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India |
| title_short | Fosfomycin susceptibility among multidrug resistant and extended spectrum β-Lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India |
| title_sort | fosfomycin susceptibility among multidrug resistant and extended spectrum β lactamase producing uropathogenic escherichia coli isolates at a tertiary care hospital of western india |
| topic | escherichia coli fosfomycin multi-drug resistance urinary tract infection |
| url | http://www.cjhr.org/article.asp?issn=2348-3334;year=2022;volume=9;issue=2;spage=125;epage=129;aulast=Jain |
| work_keys_str_mv | AT ruchijain fosfomycinsusceptibilityamongmultidrugresistantandextendedspectrumblactamaseproducinguropathogenicescherichiacoliisolatesatatertiarycarehospitalofwesternindia AT nitapal fosfomycinsusceptibilityamongmultidrugresistantandextendedspectrumblactamaseproducinguropathogenicescherichiacoliisolatesatatertiarycarehospitalofwesternindia AT sarojhooja fosfomycinsusceptibilityamongmultidrugresistantandextendedspectrumblactamaseproducinguropathogenicescherichiacoliisolatesatatertiarycarehospitalofwesternindia |